Q-omics provides the consensus-scored SRP14P2 profile across patient tissues and cancer cell-line models. SRP14P2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SRP14P2 is differentially expressed in 7, with the highest sampling consensus in LIHC. Additionally, SRP14P2 RNA expression shows 13,861 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight CESC, LIHC, and UVM as cancer lineages where SRP14P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRP14P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRP14P2 survival associations across molecular data types. SRP14P2 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRP14P2 RNA expression–survival associations across cancer types. High SRP14P2 expression shows unfavorable associations in KICH and UVM, but favorable associations in CESC, THCA, KIRC and READ. The CESC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for SRP14P2 RNA expression.
This table summarizes SRP14P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for SRP14P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRP14P2 shows lower tumor expression in KIRP and KICH and higher tumor expression in LIHC, CHOL, BRCA and LUAD. The LIHC box plot shows higher SRP14P2 RNA expression in tumor versus normal tissue (log2 FC = +0.508, t-test p < 0.001).
This table shows molecular features associated with SRP14P2 in patient tissues and cancer cell lines. In patient samples, SRP14P2 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
